

PROPOSED EXPANSION INTO NEW BUSINESS



IMPORTANT NOTICE

Clearbridge Health Limited (the “Company”) is a company listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the “SGX-ST”).

This presentation has been prepared by the Company and has been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with Rules 226 (2)(b) and 753 (2) of the SGX-ST Listing Manual Section B: Rules of Catalist.

This presentation has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this presentation, including the correctness of any of the statements or opinions made or reports contained in this presentation.

The contact person for the Sponsor is Mr. David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.

All statements other than statements of historical facts included in this presentation are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as “expect”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “plan”, “strategy”, “forecast” and similar expressions or future or conditional verbs such as “if”, “will”, “would”, “should”, “could”, “may” and “might”. These statements reflect the Company’s current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements. Further, the Company and the Sponsor disclaim any responsibility to update or revise any forward-looking statements for any reason, even if new information becomes available or other events occur in the future, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.


The reader(s) of this presentation should consult his or her own independent professional advisers about the issues discussed herein. Neither this presentation nor any part of its contents may be used, reproduced, disclosed or distributed to any other person without the prior written consent of the Company. The Company does not make any representation or warranty, expressed or implied, as to the accuracy of the information contained herein, and expressly disclaims any and all liability based, in whole or in part, on such information, errors therein or omissions therefrom. The information contained in this presentation has not been independently verified and it is not the intention for this presentation to be a complete or comprehensive analysis of the Company’s business, financial position or results of operations.

This presentation does not constitute, or form any part of an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

The information and opinions provided in this presentation is accurate as at the date of this presentation and are subject to change without notice.

PROPOSED EXPANSION

- The Group’s existing business has delivered a **compound annual growth rate of 401.2%** in revenue from S\$288,000 in 2017 to **S\$36,258,000** in 2020
- While remaining committed to the existing business, the Group proposes to expand into the business of **investing** into various entities in the **global healthcare sector** which are **EBITDA positive or at an inflection point with a clear line of sight to profitability** and **growing** such entities with a view towards **eventually exiting** (the “**Proposed New Business**”)
- The **existing core business will continue to form core sources of income** of the Group while the Proposed New Business will adopt an **enhanced growth strategy** in investing, growing and divesting entities in the healthcare sector



Existing Business (“Core”)

Proposed New Business (“Plus”)

PROPOSED NEW BUSINESS OVERVIEW



INVEST

- **Portfolio Companies:** entities in the global healthcare sectors which are **EBITDA positive or at an inflection point with a clear line of sight to profitability**
- **Investment size and strategies:** majority stake or minority holdings in the form of equity, debt or a hybrid in various structures e.g. joint ventures, partnerships, co-investments, and the formation of strategic alliances with parties in various countries



GROW

- Provide support to the Portfolio Companies' **operations and business** in various areas e.g. **research and development, business development, market and commercialization strategies, investment strategy, and financial planning**
- Portfolio Companies may **leverage on the Group's capabilities and networks** in the Existing Business to scale their operations and business



DIVEST

- **Exit strategies:** through mergers and acquisitions, listings on public stock exchanges, trade sales, etc.
- Portfolio Companies with **synergistic value** may be **packaged together to achieve a collective divestment**
- Assessment may be made to determine if an entity within the Group should be **reclassified between Existing Business and the Proposed New Business** with a view to **maximise shareholders' value**

RATIONALE OF EXPANSION



Potential in the Proposed New Business

- Enable the Group to better participate in the growth prospects of the global healthcare sector
- **Create synergies** between the Existing Business and the Proposed New Business
- Portfolio Companies may also be able to provide **complementary support** to **enhance the performance** of the **Existing Business**




Attractive value and opportunities in the Proposed New Business

- Allow the Group to carry out investments in the **development of a wide array of healthcare products to address healthcare needs**, including but not limited to, diagnostic tests for endemic diseases, vaccines, pandemic swabbing booths, personalised healthcare test and products/services, and digital healthcare



Additional revenue stream and flexibility for the Group

- Additional revenue streams for the Group which are likely to include profit margins derived from its exit from the Portfolio Companies
- A more **diversified business portfolio and income base for future growth**
- **Reduce the Group's reliance on its Existing Business** for its revenue streams
- Allow the Group to be **more resilient in the face of challenging times**



Enhanced shareholders' value

- **Additional funds** generated from additional revenue streams, which can be channelled towards the **enhancement of shareholders' value over the long term**

MANAGEMENT OF PROPOSED NEW BUSINESS



JEREMY YEE

Executive Director and Chief Executive Officer (CEO)

- Currently responsible for the overall operations of the Group as its Executive Director and CEO
- Experienced in identifying, spearheading and implementing company-wide business growth strategies
- Well positioned to implement the business plans in relation to the Proposed New Business
- Leadership experience in various listed companies both in Singapore and Australia to grow the Proposed New Business



JONATHAN LIAU

Chief Operating Officer (COO)

- Currently responsible for overseeing the commercial strategy and development of the Group as its COO
- Previously involved in portfolio management in the medical technology and biopharmaceutical fields at a well-established corporate investment arm of Singapore Economic Development Board
- Previously a director of corporate development and chief operating officer of other listed companies within the healthcare sector

FUNDING AND RISK FACTORS

Funding for the Proposed New Business

- Through a combination of internal resources and external funding such as capital raising, borrowings from financial institutions and other sources
- The management will determine the optimal mix of internal and external funding, taking into account the cash flow of the Company and prevailing bank borrowing costs
- The Company may also consider tapping the capital markets in various ways, including but not limited to, issuance of securities for cash by way of rights issues and placements and issuance of debt instruments as and when necessary and deemed appropriate

Risk Factors

- In undertaking the Proposed New Business, the Group could be affected by a number of risks which relate to the Proposed New Business as well as those which may generally arise from, inter alia, economic, business, market and political factors
- A summary of risk factors in relation to the Proposed New Business is as follows (please refer to shareholders' circular for more details):
 - The Proposed New Business has inherent risks associated with investing in entities
 - The Company's investment in the securities in relation to the Proposed New Business may be illiquid
 - The Proposed New Business has to cope with rapidly evolving technologies and market trends
 - The Proposed New Business may require substantial capital investments or cash outlay
 - The Group's performance following the proposed expansion will be subject to exposure to macro-economic risks
- The risks described above and in the shareholders' circular are not intended to be exhaustive and are not presented in any particular order of importance

END OF PRESENTATION

Tel: 6251 0136

Add: 37 Jalan Pemimpin #08-05 Mapex
Singapore 577177